Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieran F Docherty

Showing results (81-90 of 174) with videos related to

Pageof 18
Sort By:
JACC. Heart Failure|February 4, 2022
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HFKieran F Docherty, Joanne Simpson, Pardeep S Jhund, et al.
JAMA Cardiology|July 28, 2021
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical TrialKieran F Docherty, Pardeep S Jhund, Brian Claggett, et al.
European Heart Journal|August 29, 2025
Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failureKieran F Docherty, Benjamin Heywood, Antoni Bayes-Genis, et al.
European Heart Journal|August 31, 2025
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
European Journal of Heart Failure|July 29, 2020
Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERESøren Lund Kristensen, Davide Castagno, Li Shen, et al.
JACC. Heart Failure|April 15, 2019
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection FractionLi Shen, Pardeep S Jhund, Kieran F Docherty, et al.
JACC. Heart Failure|January 13, 2026
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Lancet (London, England)|August 30, 2022
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsMuthiah Vaduganathan, Kieran F Docherty, Brian L Claggett, et al.
Circulation. Heart Failure|August 30, 2024
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE TrialsKieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 7, 2023
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studiesJoanna Osmanska, Katriona Brooksbank, Kieran F Docherty, et al.
Pageof 18

Showing results (81-90 of 174) with videos related to

Sort By:
Pageof 18
JACC. Heart Failure|February 4, 2022
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HFKieran F Docherty, Joanne Simpson, Pardeep S Jhund, et al.
JAMA Cardiology|July 28, 2021
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical TrialKieran F Docherty, Pardeep S Jhund, Brian Claggett, et al.
European Heart Journal|August 29, 2025
Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failureKieran F Docherty, Benjamin Heywood, Antoni Bayes-Genis, et al.
European Heart Journal|August 31, 2025
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
European Journal of Heart Failure|July 29, 2020
Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERESøren Lund Kristensen, Davide Castagno, Li Shen, et al.
JACC. Heart Failure|April 15, 2019
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection FractionLi Shen, Pardeep S Jhund, Kieran F Docherty, et al.
JACC. Heart Failure|January 13, 2026
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Lancet (London, England)|August 30, 2022
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsMuthiah Vaduganathan, Kieran F Docherty, Brian L Claggett, et al.
Circulation. Heart Failure|August 30, 2024
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE TrialsKieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 7, 2023
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studiesJoanna Osmanska, Katriona Brooksbank, Kieran F Docherty, et al.
Pageof 18